Seattle, WA — Global supercomputer leader Cray Inc. announced an order for a 32-processor Cray SV1(TM) supercomputer from BioNumerik Pharmaceuticals, Inc. The order includes an option to acquire future Cray Inc. technologies. Financial terms were not disclosed.
BioNumerik will use the new Cray SV1 system – which nearly doubles its existing computing capacity, memory and bandwidth – to tackle even larger quantum chemistry problems critical for creating new cancer-fighting drugs. Specifically, BioNumerik runs complex GAUSSIAN, AMBER and its own proprietary applications on its Cray supercomputers and then tests the system’s predictions in the lab. By blending the latest lab technologies with high-performance computing, BioNumerik is working to significantly shorten development time and more cost-effectively create new potentially life-saving drugs.
Installation and acceptance of the Cray SV1 supercomputer at BioNumerik’s San Antonio, Texas, facility was completed in December 2000.
The Cray SV1 supercomputer was voted one of the “Best Supercomputers” for 2000 by the readership of Scientific Computing & Instrumentation magazine. Co-winner of the award was the Cray T3E(TM) product. More than 100 Cray SV1 systems have been installed since general availability began in August 1999. Half of that volume has come from outside of the United States.
About Cray Inc.
Cray Inc. designs, builds and sells high-performance MPP, vector processor and general-purpose parallel computer systems. The company has leading edge technology, multiple product platforms, nearly 900 employees, a $2 billion installed base of approximately 600 computers worldwide, major manufacturing and service capabilities and extensive global customer relationships. Cray believes its Multithreaded Architecture and Cray T3E and Cray SV(TM) product lines together represent the future of supercomputing. Go to www.cray.com for more information on the company. Cray is a registered trademark, and Cray T3E, Cray SV1, Cray MTA and Cray SV2 are trademarks, of Cray Inc. All other trademarks are the property of their respective owners.
Safe Harbor Statement
This press release contains forward-looking statements. There are certain factors that could cause Cray’s execution plans to differ materially from those anticipated by the statements above. Among such risk factors are expected delivery and acceptance times, and timely availability of commercially acceptable components from third party suppliers. For a discussion of such risks, and other risks that could affect Cray’s future performance, please see “Risk Factors” in Cray Inc.’s most recent SEC Form 10-Q.